Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis

Article ID	Journal	Published Year	Pages	File Type
8750727	Respiratory Investigation	2018	7 Pages	PDF

Abstract

MMF is currently not approved for the treatment of SSc-ILD in Japan. Both MMF and cyclophosphamide were effective against ILD associated with SSc and, in particular, MMF was useful in terms of tolerability. When MMF is approved, it should be positioned as one of the first treatment options for SSc-ILD, which will further enhance the treatment of this disease in Japan.

Keywords

SLS SSC TLC FVC MMF DLCO ILD systemic sclerosis Interstitial lung disease Interstitial lung diseases Alveolar volume Cyclophosphamide diffusing capacity of the lung for carbon monoxide forced vital capacity Total lung capacity mycophenolate mofetil